Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
Authors:
- Nader PerroudNPNader Perroud
- Rudolf UherRURudolf Uher
- Marcella RietschelMRMarcella Rietschel
- Ole MorsOMOle Mors
- Neven HenigsbergNHNeven Henigsberg
- Joanna HauserJHJoanna Hauser
- Wolfgang MaierWMWolfgang Maier
- Daniel SoueryDSDaniel Souery
- Anna PlacentinoAPAnna Placentino
- Aleksandra SzczepankiewiczAleksandra Szczepankiewicz
- Lisbeth JorgensenLJLisbeth Jorgensen
Open Access
- 15 October 2009
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 60
Abstract
Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment. In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline. Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI. Increases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment. EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).Keywords
This publication has 38 references indexed in Scilit:
- Fluoxetine and Adult Suicidality RevisitedJournal of Clinical Psychopharmacology, 2007
- Measuring depression: comparison and integration of three scales in the GENDEP studyPsychological Medicine, 2007
- Effect of Age at Onset on the Course of Major Depressive DisorderAmerican Journal of Psychiatry, 2007
- Suicidality Scores During Double-Blind Fluoxetine and Desipramine Treatment in Mexican AmericansJournal of Clinical Psychopharmacology, 2007
- Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control studyBMJ, 2005
- Selective Serotonin Reuptake Inhibitors and Suicide: Is the Evidence, as with Beauty, in the Eye of the Beholder?Psychotherapy and Psychosomatics, 2003
- Antidepressant medication and suicide in SwedenPharmacoepidemiology and Drug Safety, 2001
- Gender Differences in Treatment Response to Sertraline Versus Imipramine in Chronic DepressionAmerican Journal of Psychiatry, 2000
- Mental disorders and suicide preventionPsychiatry and Clinical Neurosciences, 1995
- The validity of diagnostic systems for common mental disorders: a comparison between the ID-CATEGO and the DSM-III systemsPsychological Medicine, 1990